Details

Autor(en) / Beteiligte

• Buti, Sebastiano
• Bersanelli, Melissa
• Viansone, Alessandro
• Leonetti, Alessandro
• Masini, Cristina
• Ratta, Raffaele
• Procopio, Giuseppe
• Maines, Francesca
• Iacovelli, Roberto
• Ciccarese, Chiara
• Vitale, Maria Giuseppa
• De Giorgi, Ugo
• Mucciarini, Claudia
• Maruzzo, Marco
• Prati, Giuseppe
• Lattanzi, Elisabetta
• Ciammella, Patrizia
• Bruni, Alessio
• Andreani, Stefano
• D'Abbiero, Nunziata

Titel

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Ist Teil von

• Cancer treatment and research communications, 2020, Vol.22, p.100161-100161, Article 100161

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• stereotactic body radiation therapy (SBRT) use has increased overtime for the management of metastatic renal cell carcinoma (mRCC) patients, with a likely good control of irradiated lesions. We planned a retrospective multicenter Italian study, with the aim of investigating the outcome of treatment with SBRT for non-brain secondary lesions in mRCC patients. all consecutive metastatic non-brain lesions from mRCC that underwent SBRT at nine Italian institutions from January 2015 to June 2017 were considered. The primary endpoint of the study was the lesion-PFS, calculated from SBRT initiation to the local progression of the irradiated lesion. 57 extracranial metastatic lesions from 48 patients with primary mRCC were treated with SBRT. At the median follow-up of 26.4 months, the median lesion-PFS was not reached (43 censored); 72.4% of lesions were progression-free at 40 months, with significantly better lesion-PFS for small metastatic lesions (<14 mm). SBRT was safe and the 1-year local disease control was 87.7%. After SBRT, 18 patients (37.5%) permanently interrupted systemic therapy. consistently with the previous literature, our findings support the use of SBRT in selected mRCC patients.